Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ akathisia ‐ short term (up… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Cost‐effectiveness (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (long term) ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Extrapyramidal effects ‐ concomitant anticholinergic medication ‐ short term (up to 12 weeks) Participants requiring concomitant anticholinergic medication · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ concomitant… compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Relapse ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Eradication of P aeruginosa from the respiratory tract: number of participants eradicated after three month treatment phase · children with cystic fibrosis and a new culture positive for P aeruginosa
Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in eradication of P aeruginosa from the respiratory tract: number of… compared with TNS plus oral placebo (low certainty).
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review
FVC (% predicted) Change from baseline · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review
no estimate extracted
18 participants
Low
Change in weight (kg) · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · children with cystic fibrosis and a new culture positive for P aeruginosa
Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with TNS plus oral placebo (moderate certainty).
1 finding from 1 review
Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review
Number experiencing adverse effects · children with cystic fibrosis and a new culture positive for P aeruginosa
Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in adverse effects of antibiotics: number of participants experiencing… compared with TNS plus oral placebo (moderate certainty).
1 finding from 1 review
End‐product score Modified Welling scale · surgical trainees
1 finding from 1 review